NEW YORK, NY (August 8, 2019): The 20th International Conference on Alzheimer's Drug Discovery, a two-day interdisciplinary forum to be held September 16-17, 2019 in Jersey City, NJ, will bring together 20 top researchers to present a diversity of approaches and the latest on innovative treatments and diagnostics for Alzheimer's disease, related dementias and cognitive aging.
The Alzheimer's Drug Discovery Foundation (ADDF)-funded investigators and other guest speakers will share findings on both novel and repurposed drug programs and biomarkers at various stages of the pipeline.
The program will focus on four major topics that include: Small molecule approaches for Alzheimer's disease; Novel approaches for frontotemporal dementia; Clinical trials in Alzheimer's disease; Novel biomarker approaches.
"This year's conference is particularly significant," said Dr. Howard Fillit, ADDF's Founding Executive Director and Chief Science Officer.
"Research advances are rapidly bringing drug discovery closer to important and practical applications.
Several presentations will address new directions in academic and startup drug development programs, targeting a wide variety of areas including vascular pathology, calcium regulation, neuroprotection and inflammation."